Loading clinical trials...

A Study to Evaluate Safety, Tolerability and Pharmacokinetics of ADC3680B in Subjects With Partly Controlled Atopic Asthma | Clinical Trials | Clareo Health

COMPLETEDPHASE2

A Study to Evaluate Safety, Tolerability and Pharmacokinetics of ADC3680B in Subjects With Partly Controlled Atopic Asthma

A Randomised, Placebo-Controlled, Double-Blind, Parallel Group Phase II Study to Assess the Safety, Tolerability and Pharmacokinetics of ADC3680B in Subjects With Partly Controlled Atopic Asthma

NCT01448954•Pulmagen Therapeutics

View on ClinicalTrials.gov

Summary

This study is to examine the safety, tolerability, pharmacokinetics and functional activity of ADC3680B administered once daily for 28 days in subjects with partly controlled atopic asthma.

Eligibility

Age

18 - 55 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Partially controlled mild-moderate atopic asthma
•Receiving inhaled corticosteroids
•Non-smoker or former smoker
•Males and females aged 18 to 55 years inclusive
•If female, must be of non-childbearing potential

Exclusion Criteria

•History of acute severe asthma attacks
•History of COPD
•Other serious respiratory or other medical condition which may interfere with the outcome of the study

Locations (2)

Belfast, United Kingdom

Manchester, United Kingdom

Key Dates

Start Date

September 1, 2011

Primary Completion Date

February 1, 2012

Completion Date

February 1, 2012

Last Updated

February 20, 2012

Enrollment

ESTIMATED participants

Conditions

Atopic Asthma

Interventions

ADC3680B oral

DRUG

Placebo oral

DRUG

A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough

NCT05660850

Chronic Refractory Cough (CRC) With Non-atopic AsthmaCRC With Atopic Asthma+3 more

View study

NOT_YET_RECRUITINGNA

Vibroacoustic Therapy With Oscillating Positive Expiratory Pressure in the Treatment of Nasal Congestion

NCT07114107

Atopic RhinitisAtopic Asthma

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 20, 2012Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study to Evaluate Safety, Tolerability and Pharmacokinetics of ADC3680B in Subjects With Partly Controlled Atopic Asthma

Inclusion Criteria

Exclusion Criteria

A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough

Vibroacoustic Therapy With Oscillating Positive Expiratory Pressure in the Treatment of Nasal Congestion

A Double Masked, Placebo Controlled, Single Center, Randomized Clinical Trial to Assess the Safety and Efficacy of Subjects With Mild Asthma Induced by the Bronchial Allergen Challenge (BAC)

Airway Response to Repeat Allergen Challenge and the Effect of Ibuprofen in Mild Atopic Asthma

Randomized Controlled Trial of Silymarin in Asthma

Differential Gene Expression in Lung and Peripheral Blood After Inhaled Allergen Challenge